Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rontalizumab May Help Patients with Lupus & Low Interferon Signature

  |  

Rontalizumab treatment was safe and well tolerated by all patients. There were no increases in infections or serious infections in patients treated with rontalizumab.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Kalunian KC, Merrill JT, Maciuca R, et al. A Phase 2 study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2015 Jun 2. pii: annrheumdis-2014-206090. doi: 10.1136/annrheumdis-2014-206090. [Epub ahead of print]

Related Articles

    The Type I Interferon Pathway’s Influence in Connective Tissue Disease

    Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…

    Atacicept Shows Promise in Lupus Treatment Trials

    A new biologic agent for treatment of systemic lupus erythematosus (SLE) being tested in clinical trials is showing promise as a safe and effective new treatment, particularly in patients with more severe disease or serologically active disease. Recently published results of a study that examined the safety and efficacy of atacicept for SLE showed the…